American surgeons carry out first U.S. face transplant

Ortho Biotech Products, L.P. has announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment

Full Post: Ortho Biotech submits NDA for Trabectedin in relapsed ovarian cancer

Surgeons in the United States have carried out America’s first face transplant at a clinic in Cleveland, Ohio where a woman has had 80% of her face replaced with that of a deceased female donor.

The operation which was conducted by reconstructive surgeon Dr. Maria Siemionow along with a team of seven other doctors, is only the fourth worldwide to be carried out - two have been conducted in France and one in China.

The first patient to receive a face transplant was Isabelle Dinoire, who underwent the surgery in 2005 when she was 38, after she had been mauled by her Labrador retriever - French surgeons grafted onto her face a nose, lips and chin from a donor who had been declared brain-dead.

In 2006, a 30-year-old Chinese farmer underwent a facial transplant including the connection of arteries and veins, and repair of the nose, lip and sinuses after he had been mauled by a bear and in 2007 a 29-year-old man French man underwent surgery following a facial tumour called a neurofibroma so massive that the man was unable to eat or speak properly.

The successful U.S. procedure took place recently on a patient who had been disfigured by a traumatic injury but no further information about the patient has been released.

Controversy surrounds surgery such as facial transplants which are considered to be experimental; they carry significant risks and they aim to improve a patient’s quality of life rather than as a life-saving procedure.

The risks include failure of the transplanted tissue and complications from anti-rejection drugs, which the patient must take for the rest of their life and should the anti-rejection drugs fail, surgeons have few alternatives to offer the recipient.

However transplant pioneers believe that the psychological effects of facial damage from injuries, birth defects and a number of diseases can be devastating and they say as long as the patients, donors and their families understand the risks, the benefits of an experimental face transplant may outweigh the drawbacks.

The Cleveland Clinic became the first American hospital to approve the procedure four years ago.


Who knows what evil lurks in the hearts of men? Dr. Prabir Bhattacharya and his computers might. He and Concordia graduate student Abu Sayeed Sohail are developing a computer image processing system that detects and classifies human facial expressions. The aim of this system is to take and analyze photos of individuals, potentially in areas

Full Post: New image processing system detects and classifies human facial expressions

Researchers in the U.S. have discovered a new cancer drug which effectively treats transplant rejections. The researchers from the University of Cincinnati (UC) say the new therapy for transplant patients, targets the antibody-producing plasma cells that can cause organ rejection. According to a study by Dr. Steve Woodle and colleagues, the cancer drug bortezomib which

Full Post: New therapy for transplant rejection

In what is thought to be a world-first, a British woman who was given an ovary transplant is about to give birth to her first baby. The 38-year-old Londoner underwent the pioneering whole ovary transplant in the U.S. early last year when her identical twin sister’s donated ovary was transplanted after being removed using keyhole

Full Post: Baby due as a result of first ever whole ovary transplant

Patients whose nose has been destroyed by a tumor or injury carry a severe psychological and social burden. Esthetic reconstruction ranges among the most challenging tasks in plastic surgery. Helmut Fischer and Wolfgang Gubisch present the different options for nasal reconstruction surgery in the current issue of Deutsches ?zteblatt International ( Dtsch Arztebl Int 2008;

Full Post: 7 years without a nose

For patients with an uncommon condition causing a swollen appearance of the lower face, treatment with botulinum toxin type A (Botox) provides an effective alternative to plastic surgery, according to a study in the November Journal of Craniofacial Surgery. Dr. Gianpaolo Tartaro and colleagues of Seconda Universit?egli Studi di Napoli, Italy, report on the use

Full Post: Botulinum toxin used to treat patients with masseteric muscle hypertrophy